Suppr超能文献

经冠状窦导线拔除后行心脏再同步治疗:在三级转诊中心行经静脉再植入的可行性和中期结果。

Cardiac resynchronization therapy after coronary sinus lead extraction: feasibility and mid-term outcome of transvenous reimplantation in a tertiary referral centre.

机构信息

Department of Cardiovascular Diseases, University Hospital of Pisa, Via Roma 67, Pisa, Italy.

出版信息

Europace. 2012 Apr;14(4):515-21. doi: 10.1093/europace/eur339. Epub 2011 Oct 28.

Abstract

AIMS

Few data are available on cardiac resynchronization therapy (CRT) after coronary sinus (CS) lead extraction. We aimed to evaluate the feasibility and mid-term outcome of transvenous CS lead reimplantation in a tertiary referral centre.

METHODS AND RESULTS

We enrolled all patients who were referred to our hospital for CS lead removal from December 2000 through to May 2009 and were transvenously reimplanted with a CRT system before June 2009. One-year follow-up was performed to evaluate the incidence of infections, malfunctions, and mortality. We studied 113 consecutive patients undergoing successful CS lead extraction; 90 patients (75 male, mean age 69.2, range 35-84) underwent CS lead reimplantation (success rate: 95.6%; right-sided approach: 64.4%). In these patients, cardiac device infection was the usual indication for extraction (74.4%) and the subsequent reimplantation was performed after a median time of 3 days. The coronary sinus lead was usually positioned in the left ventricular (LV) postero-lateral region (62.2%); two procedures were required in two cases (2.2%). Balloon angioplasty was necessary for two patients (failure in one), whereas for the others we used a conventional implant technique. During follow-up, we observed four cases (4.4%) of local infection and six cases (6.7%) of system malfunction, requiring reintervention (two cases during the same hospitalization). One-year mortality was 5.5%.

CONCLUSION

Left ventricular lead reimplantation is in our experience an effective and safe procedure, also in the case of right-sided approach. During follow-up, 1-year mortality was particularly low, whereas overall infection rate was higher than first implant procedures.

摘要

目的

关于经冠状窦(CS)导线拔除后的心脏再同步治疗(CRT),目前仅有少量数据。我们旨在评估在一家三级转诊中心经静脉 CS 导线重新植入的可行性和中期结果。

方法和结果

我们纳入了所有于 2000 年 12 月至 2009 年 5 月因 CS 导线移除而转至我院的患者,并于 2009 年 6 月前经静脉重新植入 CRT 系统。进行了为期 1 年的随访,以评估感染、故障和死亡率的发生率。我们研究了 113 例连续接受成功 CS 导线拔除的患者;90 例(75 例男性,平均年龄 69.2 岁,范围 35-84 岁)接受 CS 导线重新植入(成功率:95.6%;右侧入路:64.4%)。在这些患者中,心脏器械感染是最常见的拔除指征(74.4%),随后在中位时间 3 天后进行了再植入。CS 导线通常放置在左心室(LV)后侧区域(62.2%);在 2 例患者(2.2%)中需要进行 2 次手术。有 2 例患者(1 例失败)需要球囊血管成形术,而对于其他患者,我们采用了常规植入技术。在随访期间,我们观察到 4 例(4.4%)局部感染和 6 例(6.7%)系统故障,需要再次干预(2 例在同一住院期间)。1 年死亡率为 5.5%。

结论

在我们的经验中,左心室导线再植入是一种有效且安全的程序,即使采用右侧入路也是如此。在随访期间,1 年死亡率特别低,而总感染率高于初次植入手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验